Effect of cut‐out rescan procedures on the accuracy of an intraoral scanner used for digitizing an ear model: An in vitro study

alexandrossfakianakis shared this article with you from Inoreader Effect of cut‐out rescan procedures on the accuracy of an intraoral scanner used for digitizing an ear model: An in vitro study via Journal of Prosthodontics Abstract Purpose The purpose of this study was to evaluate the impact of the rescanning of mesh holes of different diameters on the accuracy of an intraoral scanner (IOS) used to digitize an ear model. Materials and methods An ear model was digitized using an intraoral scanner (Medit i500) to obtain a reference mesh. A baseline experimental scan was created by editing a duplicate of the reference mesh using the cut-out tool of the IOS software. Three equal groups were created based on the diameter of the cut-out areas: 2-mm (G1), 5mm (G2), and 8-mm (G3) (n = 15). The cut-out areas were rescanned and a total of 45 digital files were exported. The discrepancy between the reference and the experimental digital scans was measured using the root mean square calculation (RMS). The data were analyzed by a Kruskal–Wallis test followed by a post hoc Dunn's test with Bonferroni correction. Results The trueness values ranged from 19.53 to 27.13 μm. There were significant differences in the RMS error values among the groups tested (p<.001) and post hoc multiple comparisons showed significant differences between the G1 and G2 groups (p = .04), G1 and G3 groups (p<.001), and G2 and G3 groups (p = .004). Overall, the precision values ranged from 4.93 to 7.73 μm and significant differences in the RMS values were only found between the G1 and G2 groups (p = .014). Conclusions Mesh hole rescanning affected the scanning accuracy (trueness and precision) of the IOS tested. The larger the diameter of the mesh holes, the less the trueness of the IOS tested. The precision values seemed to be less affected compared with the trueness by the cut-out and rescanning procedures. This article is protected by copyright. All rights reserved View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Influence of geometric dimensions on early failures of adhesively retained composite resin core build‐ups

alexandrossfakianakis shared this article with you from Inoreader Influence of geometric dimensions on early failures of adhesively retained composite resin core build‐ups via Journal of Esthetic and Restorative Dentistry Abstract Objective To determine the influence of the geometric dimensions of core build-ups on early core build-up failure, that is, loss before definitive prosthesis cementation. Materials and Methods Adhesive core build-ups of exclusively vital teeth in 114 participants were evaluated (n materials: 40 Rebilda DC, 38 Multicore Flow, 36 Clearfil DC Core; n teeth: 8 incisors, 54 premolars, 52 molars). Impressions of the abutment teeth were made (1) after removal of insufficient restorations/caries and (2) after core build-up and preparation for a fixed prosthesis. Digitized model surfaces of both situations were aligned (Geomagic Design X) and core build-up volume (V CBU), remaining hard tissue volume (V Abut), and size of the adhesive surface (A adh) were assessed. The derived measure d CBU = V CBU/A adh can be interpreted as mean arithmetic core build-up thickness. Associations between participant or core build-up design characteristics and the occurrence of early failures were statistically evaluated (SPSS v27, α = 0.05). Results A total of six (5.3%) core build-up failures were registered. Higher participant age, greater core build-up volume V CBU and greater arithmetic uniform thickness d CBU were associated with a greater incidence of failure in bivariate and univariate, however, not in multivariate statistics. Conclusions Core build-up volume and thickness were associated with early success or failure. Clinical Significance In the case of voluminous/thick core build-ups in relation to the adhesive surface, additional measures, such as the preparation of retentive elements to increase the bonding area, might be considered to reduce the risk of early core build-up failure. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

An overview of three‐dimensional imaging devices in dentistry

alexandrossfakianakis shared this article with you from Inoreader An overview of three‐dimensional imaging devices in dentistry via Journal of Esthetic and Restorative Dentistry Abstract Objective To review four types of three-dimensional imaging devices: intraoral scanners, extraoral scanners, cone-beam computed tomography (CBCT), and facial scanners, in terms of their development, technologies, advantages, disadvantages, accuracy, influencing factors, and applications in dentistry. Methods PubMed (National Library of Medicine) and Google Scholar databases were searched. Additionally, the scanner manufacturers' websites were accessed to obtain relevant data. Four authors independently selected the articles, books, and websites. To exclude duplicates and scrutinize the data, they were uploaded to Mendeley Data. In total, 135 articles, two books, and 17 websites were included. Results Research and clinical practice have shown that oral and facial scanners and CBCT can be used widely in various areas of dentistry with high accuracy. Conclusion Although further advancement of these devices is desirable, there is no doubt that digital technology represents the future of dentistry. Furthermore, the combined use of different devices may bring dentistry into a new era. These four devices will play a significant role in clinical utility with high accuracy. The combined use of these devices should be explored further. Clinical significance The four devices will play a significant role in clinical use with high accuracy. The combined use of these devices should be explored further. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Clinical features, treatment outcomes and prognostic factors of allopurinol‐induced DRESS

alexandrossfakianakis shared this article with you from Inoreader Clinical features, treatment outcomes and prognostic factors of allopurinol‐induced DRESS in 52 patients via Journal of Clinical Pharmacy and Therapeutics This study included 52 patients. The average age of the patients was 56.1 ± 17.1 years. The ratio of men to women was 3.7 to 1. The mean of latency periods was 24.6 ± 15.0 days. Most patients presented with fever and skin rash in association with facial edema, lymphadenopathy, leukocytosis, eosinophilia, and atypical lymphocytosis. Liver and kidney injury were the most common visceral manifestation. Pulmonary involvement, cardiac involvement and gastrointestinal involvement were relatively less known but severe complications. Two patients showed nervous system involved. HLA-B*5801 allele was tested in 18 patients. 88.9% (16/18) of cases were positive. 92.3% (48/52) of patients were treated with oral glucocorticoids. 25.0% of patients were died. Advanced age, underlying cardiovascular disease, chronic kidney disease and high dose of allopurinol, infection and internal organ involvement (including kidney, heart, lung and gastrointestinal tract) were risk factors for death. Abstract What is Known and Objective Allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but serious and potentially life-threatening drug hypersensitivity syndrome. In this study, we aimed to investigate the clinical features, treatment outcomes, and prognostic factors of allopurinol-induced DRESS. Methods Case reports of allopurinol-induced DRESS published by China from January 2000 to August 2021 were retrieved from CNKI, Wan Fang, VIP, and PubMed databases for analysis. Results and Discussion This study included 52 patients, consisting of 41 (78.8%) males and 11 (21.2%) females (M:F = 3.7:1). The mean of age was 56.1 ± 17.1 years (range: 18–86 years). The mean of latency periods was 24.6 ± 15.0 days (range:1-63 days). Most patients presented with fever, cutaneous eruption, eosinophilia, lymphadenopathy, and facial edema. 36/52 (69.2%) patients showed two or more internal organs involved. Liver and kidney injuries were the most common visceral manifestation. Pulmonary involvement (34.6%), cardiac involvement (25.0%) and gastrointestinal involvement (21.2%) were relatively less known but severe complications. 2/52 (3.8%) patients showed nervous system involved, presenting as leukoencephalopathy or peripheral neuropathy. 2/52 (3.8%) patients presented with secondary hemophagocytic lymphohistiocytosis.1/52 (1.9%) patient developed pure red cell aplasia and 1/52 (1.9%) patient developed painless thyroiditis. HLA*B 58:01 allele was tested in 18/ 52 (34.6%) patients. 16/18 (88.9%) cases were positive. 48/52 (92.3%) patients were treated with systemic corticosteroids. 16/52 (30.8%) patients were cured, 23/52 (44.2%) patients received partial recovery, and 13/52 (25.0%) patients were died. Septic shock, gastrointestinal bleeding and multiple organ failure were the leading causes of death. Advanced age, underlying cardiovascular disease, chronic kidney disease and high dose of allopurinol, infection and internal organ involvement (including kidney, heart, lung and gastrointestinal tract) were risk factors for death. What is New and Conclusion We explored clinical features, treatment outcomes and prognostic factors of 52 allopurinol-induced DRESS cases in China. Ethnicity, especially Han Chinese, and positive HLA-B*58:01 allele are the clearest risk factors so far. Advanced age, underlying cardiovascular disease, chronic kidney disease and high dose of allopurinol, infection and internal organ involvement (including kidney, heart, lung and gastrointestinal tract) were associated with poorer outcomes. Early identification and discontinuation of the causative drug are crucial to the management of DRESS. For patients with severe disease, corticosteroids are recommended as the first-line therapy. However, further studies are needed to address diagnostic criteria of DRESS for early diagnosis, as well as to develop standardized corticosteroid treatment regimens. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Evaluation of off‐label anti‐vascular endothelial growth factor and steroid implant medication uses in macular edema due to retinal vein occlusion

alexandrossfakianakis shared this article with you from Inoreader Evaluation of off‐label anti‐vascular endothelial growth factor and steroid implant medication uses in macular edema due to retinal vein occlusion in Turkey via Journal of Clinical Pharmacy and Therapeutics Retinal vein occlusion (RVO) is one of the most common causes of vision loss. Anti-vascular endothelial growth factor (anti-VEGF) drugs and corticosteroid implants are approved as the standard treatment options for RVO. In this study, we aimed to review the applications for off-label drug use for RVO to the Turkish Medicines and Medical Devices Agency in 2018. Majority of the drugs requested for off-label use were anti-VEGF agents, followed by a potent corticosteroid dexamethasone implant. No applications were made for bevacizumab since its use does not require official permission. In the beginning of the 2019, substantial regulations were imposed for the intravitreal drug use principles for RVO in Turkey. Administration of three consecutive doses of off-label bevacizumab have become mandatory before utilizing licensed drugs for RVO (ranibizumab, aflibercept and dexamethasone implant). This study reports off-label drug preferences and previous and current principles of drug use fo r RVO in Turkey. Abstract What is Known and Objective Retinal vein occlusion (RVO) is one of the most common causes of vision loss. Anti-vascular endothelial growth factor (anti-VEGF) drugs, ranibizumab and aflibercept, and corticosteroid implants are approved treatment options for RVO-related macular edema (ME) in Turkey. To the best of our knowledge, there is no data regarding the off-label use of these drugs for RVO in English literature. We aimed to evaluate the clinical and demographic characteristics of off-label drug use applications in Turkey for RVO. Methods Applications made to the Turkish Medicines and Medical Devices Agency between January 1 and December 31, 2018, for the use of off-label drugs (ranibizumab, aflibercept, dexamethasone implant) for the diagnosis of RVO from hospitals across Turkey were retrospectively analysed. Data of the applications, such as demographic characteristics, previous treatment regimens, reasons for applications, applicant hospitals and their regions, were recorded. Results There were 291 approved applications for RVO. The mean age of the patients was 64.88 ± 10.78 years, 48.8% were male, and 51.2% were female. Of these applications, 44.7% were for aflibercept, 35.7% for ranibizumab and 19.6% for dexamethasone implant. No application was made for bevacizumab since it could be used without needing for an application. The most common reasons for applications were due to dose limitations, failure to complete loading doses, and glaucoma, respectively. In terms of the distribution of the applicant hospitals, public university hospitals ranked first with 72.5%, training and research hospitals ranked second with 14.7% and foundation university hospitals ranked third with 13.1% rates. What is New and Conclusion The practice of drug use in RVO in Turkey has changed as of the beginning of 2019. Stepwise therapy has been accepted by the drug regulatory agency Turkish Medicines and Medical Devices Agency. Utilization of licensed drugs, aflibercept, ranibizumab and dexamethasone has been allowed only after administration of 3 doses of intravitreal bevacizumab. After 3 doses of bevacizumab, the physician may continue either with bevacizumab again or a dexamethasone implant. If there is a reason such as the presence of glaucoma, the physician may skip dexamethasone and switch to aflibercept and ranibizumab, but in this case, dexamethasone cannot be administered to the patient for life. The evaluation of the off-label treatments of RVO, which is one of the most frequently followed diseases in retina clinics, not only contributes to the literature but also provides information regarding the most frequently applied treatments and the physicians' off-label drug preferences for RVO. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Stability of nasal symmetry following primary cleft lip and nasal repair: five years of follow-up

alexandrossfakianakis shared this article with you from Inoreader Stability of nasal symmetry following primary cleft lip and nasal repair: five years of follow-up via International Journal of Oral and Maxillofacial Surgery via MedWorm.com Despite advances in cleft lip treatment, various levels of residual deformity remain after primary repair of cleft lip and palate. The aim of the current study was to compare the stability of short- and long-term postoperative nasal symmetry. This retrospective study included 100 consecutive non-syndromic patients with unilateral complete cleft lip who underwent primary cleft lip repair with follow-up of 5 years. Measurements taken from basal and frontal standard photograph views, obtained preoperatively (T1) and immediately (T2), 1 year (T3), and 5 years postoperative (T4), were analysed. (Source: International Journal of Oral and Maxillofacial Surgery) View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Periodontal ligament fibroblasts-derived exosomes induced by PGE2 inhibit human periodontal ligament stem cells osteogenic differentiation via activating miR-34c-5p/SATB2/ERK

alexandrossfakianakis shared this article with you from Inoreader Periodontal ligament fibroblasts-derived exosomes induced by PGE<sub>2</sub> inhibit human periodontal ligament stem cells osteogenic differentiation via activating miR-34c-5p/SATB2/ERK via ScienceDirect Publication: Experimental Cell Research Publication date: Available online 15 August 2022 Source: Experimental Cell Research Author(s): Chen Lin, Yingying Yang, Yingxue Wang, Heng Jing, Xinyi Bai, Zheng Hong, Chunxiang Zhang, Hui Gao, Linkun Zhang View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas

alexandrossfakianakis shared this article with you from Inoreader IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas via Neuro-Oncology Advance Access Abstract Background IDH1/2 wildtype (IDHwt) glioma WHO grade 2 and 3 patients with pTERT mutation and/or EGFR amplification and/or +7/−10 chromosome gain/loss have a similar overall survival time as IDHwt glioblastoma patients, and are both considered glioblastoma IDHwt according to the WHO 2021 classification. However, differences in seizure onset have been observed. This study aimed to compare the course of epilepsy in the two glioblastoma subtypes. Methods We analyzed epilepsy data of an existing cohort including IDHwt histologically lower-grade glioma WHO grade 2 and 3 with molecular glioblastoma-like profile (IDHwt hLGG) and IDHwt glioblastoma patients. Primary outcome was the incidence proportion of epilepsy during the disease course. Secondary outcomes included, among others, onset of epilepsy, number of seizure days and antiepileptic drug (AED) polytherapy. Results Out of 254 pa tients, 78% (50/64) IDHwt hLGG and 68% (129/190) IDHwt glioblastoma patients developed epilepsy during the disease (p=0.121). Epilepsy onset before histopathological diagnosis occurred more frequently in IDHwt hLGG compared to IDHwt glioblastoma patients (90% versus 60%, p<0.001), with a significantly longer median time to diagnosis (3.5 versus 1.3 months, p<0.001). Median total seizure days was also longer for IDHwt hLGG patients (7.0 versus 3.0, p=0.005), and they received more often AED polytherapy (32% versus 17%, p=0.028). Conclusions Although the incidence proportion of epilepsy during the entire disease course is similar, IDHwt hLGG patients show a significantly higher incidence of epilepsy before diagnosis and a significantly longer median time between first seizure and diagnosis compared to IDHwt glioblastoma patients, indicating a distinct clinical course. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Translational Significance of CDKN2A/B Homozygous Deletion in IDH-Mutant Astrocytoma

alexandrossfakianakis shared this article with you from Inoreader Translational Significance of CDKN2A/B Homozygous Deletion in IDH-Mutant Astrocytoma via Neuro-Oncology Advance Access Abstract Isocitrate dehydrogenase (IDH) 1 or 2 mutations confer a favorable prognosis compared to IDH-wildtype in astrocytoma, frequently denoting a lower grade malignancy. However, recent molecular profiling has identified specific aggressive tumor subgroups with clear clinical prognostic implications that are independent of histologic grading. The homozygous deletion of CDKN2A/B is the strongest implicated independent indicator of poor prognosis within IDH-mutant astrocytoma, and the identification of this alteration in these lower histologic grade tumors transforms their biology toward an aggressive grade 4 phenotype clinically. CDKN2A/B homozygous deletion is now sufficient to define a grade 4 tumor in IDH-mutant astrocytomas regardless of histologic appearance, yet there are currently no effective molecularly informed targeted therapies for these tumors. The biologic impact of CDKN2A/B homozygous deletion in IDH-mutant tumors and the optimal treatmen t strategy for this molecular subgroup remains insufficiently explored. Here we review the current understanding of the translational significance of homozygous deletion of CDKN2A/B gene expression in IDH-mutant astrocytoma and associated diagnostic and therapeutic implications. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.